StockData
Tevogen Inc. logo

Tevogen Inc. (TVGNW) stock

TVGNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as TVGN
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$0.09+0.01 (+18.24%)

Close on Oct 30, 2026Market cap $38.42MP/E –Yield –

Earnings

Tevogen's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Tevogen's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2024ended Mar 31, 2024Apr 26, 2024before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Tevogen has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Tevogen puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Tevogen filed with the SEC as exhibits to Form 8-K or 6-K

  1. Regains Compliance with Nasdaq Global Market Continued Listing Requirements
    News
  2. N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced
    Update
  3. Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
    Update
  4. Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility
    Update
  5. Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
    Update
  6. Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
    Results
  7. Paratus Acquisition Corporation’s Shareholders Approve Business Combination with Tevogen Bio
    Update
  8. Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq
    Update
  9. Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration
    Update
  10. 8-K exhibit EX-99.1
    Update
  11. Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement
    News
  12. Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen
    Update
  13. Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation
    Update
  14. Semper Paratus Acquisition Corporation Announces
    News
  15. REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
    News